Wedge Capital Management L L P NC bought a new position in shares of Acorda Therapeutics Inc (NASDAQ:ACOR) during the first quarter, HoldingsChannel.com reports. The firm bought 36,456 shares of the biopharmaceutical company’s stock, valued at approximately $485,000.
A number of other hedge funds have also recently added to or reduced their stakes in ACOR. Ontario Teachers Pension Plan Board acquired a new stake in Acorda Therapeutics during the fourth quarter valued at approximately $1,210,000. MetLife Investment Advisors LLC boosted its holdings in Acorda Therapeutics by 55.9% during the third quarter. MetLife Investment Advisors LLC now owns 31,894 shares of the biopharmaceutical company’s stock valued at $627,000 after purchasing an additional 11,439 shares in the last quarter. Convergence Investment Partners LLC acquired a new stake in Acorda Therapeutics during the fourth quarter valued at approximately $274,000. Two Sigma Investments LP acquired a new stake in Acorda Therapeutics during the fourth quarter valued at approximately $2,509,000. Finally, Oppenheimer Asset Management Inc. acquired a new stake in Acorda Therapeutics during the fourth quarter valued at approximately $44,000.
A number of equities research analysts have weighed in on ACOR shares. HC Wainwright set a $33.00 price objective on Acorda Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 23rd. BidaskClub raised Acorda Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, February 28th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $20.00 price objective on shares of Acorda Therapeutics in a report on Friday, February 15th. Oppenheimer reaffirmed a “hold” rating on shares of Acorda Therapeutics in a report on Tuesday, March 19th. Finally, Zacks Investment Research raised Acorda Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, April 8th. Four analysts have rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $22.56.
Acorda Therapeutics (NASDAQ:ACOR) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.51. The business had revenue of $44.14 million for the quarter, compared to the consensus estimate of $35.14 million. Acorda Therapeutics had a positive return on equity of 9.34% and a negative net margin of 1.40%. Acorda Therapeutics’s revenue was down 58.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.14 EPS. On average, sell-side analysts anticipate that Acorda Therapeutics Inc will post -3.92 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Wedge Capital Management L L P NC Takes Position in Acorda Therapeutics Inc (ACOR)” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/4343118/wedge-capital-management-l-l-p-nc-takes-position-in-acorda-therapeutics-inc-acor.html.
About Acorda Therapeutics
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.
Featured Article: Stop Order Uses For Individual Investors
Want to see what other hedge funds are holding ACOR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acorda Therapeutics Inc (NASDAQ:ACOR).
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.